Eat, Shoot or Drop?
The standard of care for wet AMD presents a big burden for patients, so what other options are out there?
Lauren Robertson | | Quick Read
The Injection to End All Injections
The standard of care for wet age-related macular degeneration (AMD) is regular intravitreal injections of anti-VEGF therapy. Unfortunately, although this is effective, the burden of frequent injections for patients and caregivers means that real-world visual acuity outcomes fall short of clinical trial results because of under-dosing. This disparity has led to a push in the retina field to develop sustained delivery strategies. For the first time, gene therapy has been applied as a mechanism for drug delivery with ADVM-022, which is designed to provide long-term anti-VEGF treatment (aflibercept) with a single intravitreal injection. “The results so far have been really positive, with efficacy shown 13 months post-injection, comparable to the standard of care,” says Szilard Kiss, Director of Clinical Research and Associate Professor of Ophthalmology at Weill Cornell Medical College, New York, USA (1). The drug was found to be safe and well-tolerated (inflammation could be managed with steroid eye drops), displaying consistent and sustained anatomical improvements on OCT, without the need for any rescue injections. “In the future, the plan is to further develop the treatment for diabetic retinopathy (DR) patients as well,” adds Kiss.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.